Systemic and Antigen-Specific Immune Responses in Patients Treated with Cancer Vaccine BPX-101 Correlate with Clinical Response Read more about Systemic and Antigen-Specific Immune Responses in Patients Treated with Cancer Vaccine BPX-101 Correlate with Clinical Response
Bellicum Pharmaceuticals Announces World Renowned Clinical Advisory Board Appointments Read more about Bellicum Pharmaceuticals Announces World Renowned Clinical Advisory Board Appointments
Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding Read more about Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding
Bellicum Pharmaceuticals Awarded $5.7 Million by the Cancer Prevention and Research Institute of Texas Read more about Bellicum Pharmaceuticals Awarded $5.7 Million by the Cancer Prevention and Research Institute of Texas
Clinical Responses Demonstrated in Metastatic Castrate Resistant Prostate Cancer Patients Treated with BPX-101 Cancer Vaccine Read more about Clinical Responses Demonstrated in Metastatic Castrate Resistant Prostate Cancer Patients Treated with BPX-101 Cancer Vaccine
Journal of Clinical Investigation Publishes Data Demonstrating Enhanced Antitumor Efficacy of Second Generation DeCIDe™ Technology Read more about Journal of Clinical Investigation Publishes Data Demonstrating Enhanced Antitumor Efficacy of Second Generation DeCIDe™ Technology
Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients Read more about Bellicum Announces Publication in The New England Journal of Medicine Demonstrating Complete Reversal of Serious Immune Condition in Hematopoietic Stem Cell Transplant Patients
Bellicum Closes $20 Million Series B Financing Read more about Bellicum Closes $20 Million Series B Financing
Bellicum Appoints Baylor College of Medicine’s David M. Spencer as Chief Scientific Officer Read more about Bellicum Appoints Baylor College of Medicine’s David M. Spencer as Chief Scientific Officer
Bellicum Pharmaceuticals Initiates Clinical Trial with Novel Controlled Dendritic Cell Immunotherapy in Metastatic Castrate Resistant Prostate Cancer Read more about Bellicum Pharmaceuticals Initiates Clinical Trial with Novel Controlled Dendritic Cell Immunotherapy in Metastatic Castrate Resistant Prostate Cancer